MedPageToday
MedPage Today) — CHICAGO — A mineralocorticoid receptor antagonist (MRA) was unable to further improve 3-year outcomes of acute myocardial infarction (MI) in the modern era, based on the CLEAR OASIS 9 trial.
Among heart attack survivors without…
Read More
Spironolactone Misses the Mark in Acute MI Without HF
Maribel Stoval
03:19
MedPage Today) — CHICAGO — A mineralocorticoid receptor antagonist (MRA) was unable to further improve 3-year outcomes of acute myocardial infarction (MI) in the modern era, based on the CLEAR OASIS 9 trial. Among heart attack survivors without…
